May 2009 Volume 5 Number 5
Visit Nature Reviews Neurology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=72&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Neurology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=42&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=59&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
*********************************************************************
Nature Reviews Neurology Impact Factor: 4.339*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Neuropsychopharmacology
Special Section: The May issue of Neuropsychopharmacology special themed
section: Recent Findings Relevant to Depression Research is a must read
for any psychiatric researcher examining depression. The studies offer a
"brain-centric" approach that provides fresh insights into depression.
Neuropsychopharmacology is the official journal of the American College
of Neuropsychopharmacology and is dedicated to publishing highly-ranked
research in psychiatry, neuroscience, pharmacology and pharmacy. Visit
http://links.ealert.nature.com/ctt?kn=58&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
to learn more.
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Neurodegenerative disease: The cellular prion protein: a novel target
for Alzheimer disease therapeutics?
p235 | doi:10.1038/nrneurol.2009.43
http://links.ealert.nature.com/ctt?kn=84&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
In the news: Obama's stem cell move
p236 | doi:10.1038/nrneurol.2009.42
http://links.ealert.nature.com/ctt?kn=13&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Cerebrovascular disease: Migraine in pregnancy
p236 | doi:10.1038/nrneurol.2009.47
http://links.ealert.nature.com/ctt?kn=67&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Epilepsy: A new add-on therapy for epilepsy
p237 | doi:10.1038/nrneurol.2009.45
http://links.ealert.nature.com/ctt?kn=38&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Neurodegenerative disease: A neurobiological basis for depression in
Huntington disease
p237 | doi:10.1038/nrneurol.2009.46
http://links.ealert.nature.com/ctt?kn=47&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Movement disorders: Ablative surgery for Parkinson disease
p238 | doi:10.1038/nrneurol.2009.44
http://links.ealert.nature.com/ctt?kn=79&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
IN BRIEF
Dementia | Epilepsy | Pain | Epilepsy
p238 | doi:10.1038/nrneurol.2009.48
http://links.ealert.nature.com/ctt?kn=18&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Are some antidepressants better than others?
Gerald Gartlehner and Richard A. Hansen
p239 | doi:10.1038/nrneurol.2009.51
An analysis of 12 different second-generation antidepressants rated
sertraline and escitalopram as having the most favorable balance between
benefit and harm for the treatment of major depressive disorder in adults.
A second look at the methods and results from the study reveals that
such a positive conclusion might not be warranted.
http://links.ealert.nature.com/ctt?kn=53&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Migraine: Telcagepant provides new hope for people with migraine
Lars Edvinsson
p240 | doi:10.1038/nrneurol.2009.49
The triptan drugs provide effective migraine relief for many people.
Nevertheless, a substantial number of migraine-affected individuals
are unresponsive to triptans, and such therapy can also lead to an
array of adverse effects. A new class of antimigraine drugs, currently
undergoing clinical trials, could offer hope to those for whom triptan
medication is unsuitable.
http://links.ealert.nature.com/ctt?kn=44&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Parkinson disease: Pain in Parkinson disease: the hidden epidemic
Blair Ford
p242 | doi:10.1038/nrneurol.2009.50
Parkinson disease is commonly recognized as a neurodegenerative disorder
that leads to disabling motor and cognitive impairment, but less widely
appreciated is the association of this condition with a variety of pain
syndromes. A recent survey emphasizes the high prevalence and severity
of pain in patients with Parkinson disease.
http://links.ealert.nature.com/ctt?kn=32&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Alzheimer disease: Visual rating of atrophy aids diagnostic accuracy
Natalie S. Ryan and Nick C. Fox
p243 | doi:10.1038/nrneurol.2009.52
The need for early diagnosis of Alzheimer disease is gathering importance
with the prospect of disease-modifying therapy. Medial temporal lobe
atrophy on MRI is a characteristic, early and predictive feature of the
disease. A new visual rating system has been proposed to facilitate
assessment of such atrophy in routine clinical practice.
http://links.ealert.nature.com/ctt?kn=15&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Management of agitation and aggression associated with Alzheimer disease
Clive G. Ballard, Serge Gauthier, Jeffrey L. Cummings, Henry Brodaty,
George T. Grossberg, Philippe Robert and Constantine G. Lyketsos
p245 | doi:10.1038/nrneurol.2009.39
Agitation and aggression are common symptoms of Alzheimer disease (AD),
causing risk and distress to the patient and others. Atypical
antipsychotics are the most widely prescribed pharmacological treatments
for these symptoms, but they can cause harmful effects. Here, Clive Ballard
and colleagues review the risks associated with atypical antipsychotics
and present the many alternative treatments and approaches that are
available for managing agitation and aggression in AD.
Abstract: http://links.ealert.nature.com/ctt?kn=65&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=22&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials
Frederik Barkhof, Peter A. Calabresi, David H. Miller and Stephen C. Reingold
p256 | doi:10.1038/nrneurol.2009.41
Multiple sclerosis is traditionally considered to be an inflammatory
disease, but it also has a neurodegenerative component, which can manifest
early in the disease course. New therapeutic strategies are being
developed to elicit CNS neuroprotection and repair in patients with
multiple sclerosis, and Barkhof et al. review the available data on
imaging outcome measures that could be used to track the efficacy of
these approaches.
Abstract: http://links.ealert.nature.com/ctt?kn=68&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=28&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Brain mechanisms of altered conscious states during epileptic seizures
Andrea Eugenio Cavanna and Francesco Monaco
p267 | doi:10.1038/nrneurol.2009.38
Impaired consciousness is a hallmark of epileptic seizures, but the
degree of impairment differs depending on the seizure type. Here, Andrea
Cavanna and Francesco Monaco review recent insights into the brain
mechanisms that underlie alterations of consciousness during epileptic
seizures and argue that clinical assessment should take into account both
patients' levels of awareness and their subjective contents of consciousness.
Abstract: http://links.ealert.nature.com/ctt?kn=7&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=80&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
The optic nerve head in hereditary optic neuropathies
Evelyn C. O'Neill, David A. Mackey, Paul P. Connell, Alex W. Hewitt,
Helen V. Danesh-Meyer and Jonathan G. Crowston
p277 | doi:10.1038/nrneurol.2009.40
The hereditary optic neuropathies, which include dominant optic atrophy,
Leber hereditary optic neuropathy and certain types of glaucoma, result
in characteristic changes in the morphology of the optic nerve head and
the surrounding retinal nerve fiber layer. In this article, O'Neill et al.
review the currently available retinal imaging technologies and describe
the typical morphological features of the optic nerve head in various
hereditary optic neuropathies.
Abstract: http://links.ealert.nature.com/ctt?kn=82&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=49&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Intravascular lymphomatosis of the brain in a patient with myelodysplastic
syndrome
Gregorius J. Sips, Colum F. Amory, Bradley N. Delman, George M. Kleinman,
Lewis R. Lipsey and Stanley Tuhrim
p288 | doi:10.1038/nrneurol.2009.36
Sips and colleagues describe the onset of intravascular lymphomatosis (IVL)
of the brain in a 77-year-old retired research pharmacologist with a
history of anemia, pancytopenia, and a recently confirmed diagnosis of
myelodysplastic syndrome (MDS). The authors discuss the mechanisms of
IVL and MDS and possible relationships between the conditions, as well
as a beneficial effect of treatment of IVL with high-dose combination
chemotherapy and rituximab.
Abstract: http://links.ealert.nature.com/ctt?kn=4&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=48&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=27&m=32890502&r=MTc2NDUyMzIwMwS2&b=2&j=NDg1MDk0NTcS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
